AKOYA_logo_white_smallAKOYA_logo_white_smallAKOYA_logo_white_smallAKOYA_logo_white_small
  • Our Statement on COVID-19
  • Search
  • Login
  • Contact Us
  • Products
    • Solutions
      • Why Multiplex Imaging
      • Discovery to Translation
      • Biopharma Services
    • Products
      • CODEX® – Ultrahigh Multiplexed Imaging
      • PhenopticsTM – High-throughput Multiplexed Imaging
      • ProximaTM – Cloud Storage & Collaboration
  • Technology
    • Intro to CODEX
    • Intro to Phenoptics
  • Support
    • Hardware
    • Software
    • Reagents
    • FAQs
  • Resources
    • Akoya Academy
    • Literature
    • Videos
    • Webinars
    • Publications
    • Blog
  • Company
    • About Us
    • Leadership
    • Partners
    • Careers
    • News
    • Media Kit
    • Upcoming Events
  • Products
    • Codex
    • Phenoptics
    • Proxima
  • Solutions
    • Why Multiplex Imaging?
    • Discovery to Translation
    • Biopharma Services
  • Technology
    • Intro to CODEX
    • Intro to Phenoptics
  • Support
    • Hardware
    • Software
    • Reagents
    • FAQs
  • Resources
    • Akoya Academy
    • Literature
    • Videos
    • Webinars
    • Publications
    • Blog
  • Company
    • About Us
    • Leadership
    • Partners
    • Careers
    • News
    • Media Kit
    • Upcoming Events
  • Home
  • A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

Cader, F. Z., Hu, X., Goh, W. L., Wienand, K., Ouyang, J., Mandato, E., ... & Schackmann, R. C. (2020). A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nature Medicine, 26(9), 1468-1479.

Authors: Cader, Fathima Zumla; Hu, Xihao; Goh, Walter L.; Wienand, Kirsty; Ouyang, Jing; Mandato, Elisa; Redd, Robert; Lawton, Lee N.; Chen, Pei Hsuan; Weirather, Jason L.; Schackmann, Ron C. J.; Li, Bo; Ma, Wenjiang; Armand, Philippe; Rodig, Scott J.; Neuberg, Donna; Liu, X. Shirley; Shipp, Margaret A.

Online: https://doi.org/10.1038/s41591-020-1006-1

Issue: Nat Med. 2020 Sep;26(9):1468-1479.

Abstract

PD-1 blockade is highly effective in classical Hodgkin lymphomas (cHLs), which exhibit frequent copy-number gains of CD274 (PD-L1) and PDC1LG2 (PD-L2) on chromosome 9p24.1. However, in this largely MHC-class-I-negative tumor, the mechanism of action of anti-PD-1 therapy remains undefined. We utilized the complementary approaches of T cell receptor (TCR) sequencing and cytometry by time-of-flight analysis to obtain a peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 phase II clinical trial (NCT02181738). Anti-PD-1 therapy was most effective in patients with a diverse baseline TCR repertoire and an associated expansion of singleton clones during treatment. CD4+, but not CD8+, TCR diversity significantly increased during therapy, most strikingly in patients who had achieved complete responses. Additionally, patients who responded to therapy had an increased abundance of activated natural killer cells and a newly identified CD3-CD68+CD4+GrB+ subset. These studies highlight the roles of recently expanded, clonally diverse CD4+ T cells and innate effectors in the efficacy of PD-1 blockade in cHL.

 

Products

  • CODEX
  • Phenoptics
  • Proxima

Solutions

  • Why Multiplex Imaging
  • Discovery to Translation
  • Biopharma Services

Support

  • Hardware
  • Software
  • Reagents
  • FAQs

Technology

  • Intro to CODEX
  • Intro to Phenoptics

Resources

  • Akoya Academy
  • Literature
  • Videos
  • Webinars
  • Publications
  • Blog

Company

  • About Us
  • Leadership
  • Partners
  • Careers
  • News
  • Media Kit
  • Upcoming Events



Akoya Biosciences is a registered trademark and The Spatial Biology Company is a trademark of Akoya Biosciences, Inc. A Delaware corporation.
Copyright © 2019 All Rights Reserved | Terms and Conditions | Privacy Policy
    • Our Statement on COVID-19
    • Search
    • Login
    • Contact Us